Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 10:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 15,608 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Skin and Connective Tissue Disease Clear all
Not listed No phase listed Observational

The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)

NCT03896958
View directory record Official record
Conditions
Cancer, All Types, Cancer of Liver, Cancer of Stomach, Cancer of Head and Neck, Cancer of Rectum, Cancer of Kidney, Cancer of Esophagus, Cancer of Colon, Cancer Skin, Cancer of Cervix, Cancer, Metastatic, Cancer of Larynx, Cancer of Neck, Cancer of Lung, Cancer of Brain and Nervous System, Cancer of Vulva, Disseminated, Cancer of Pancreas, Sarcoma, GIST, Small-cell Lung Cancer, Adenocarcinoma Lung, Cancer of Prostate, Cancer, Advanced, Adrenal Cancer, Testicular Cancer, Uterine Cancer, Bronchoalveolar Cell Lung Cancer, Cancer Unknown Primary, Glioblastoma Multiforme, Oligodendroglioma, Breast Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma, Cholangiocarcinoma, Squamous Cell Carcinoma, Transitional Cell Carcinoma, Cancer, Other, Cancer, Anal, Melanoma, Cancer, Bile Duct, Cancer, Bladder, Cancer Cords Vocal, Cancers Cell Neuroendocrine, Cancer Differentiated Poorly, Cancer, Anaplastic Thyroid
Interventions
Not listed
Lead sponsor
SpeciCare
Industry
Eligibility
1 Month to 99 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Gainesville, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 4, 2020 · Synced Oct 31, 2026, 10:15 AM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors

NCT07145255
View directory record Official record
Conditions
Prostate Cancer Castration-resistant Prostate Cancer, Breast Cancer, Colo-rectal Cancer, Lung Cancer (Non-Small Cell), Pancreas Cancer, Duct Cell Adenocarcinoma
Interventions
ADC
Drug
Lead sponsor
MBrace Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
7
States / cities
San Francisco, California • Grand Rapids, Michigan • East Brunswick, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 31, 2026, 10:15 AM EDT
Completed Phase 2 Interventional

High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid Tumors

NCT00060255
View directory record Official record
Conditions
Breast Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Testicular Germ Cell Tumor, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
busulfan, carboplatin, carmustine, cyclophosphamide, etoposide, melphalan, thiotepa, autologous bone marrow transplantation, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
4 Years and older
Enrollment
451 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2013
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 9, 2013 · Synced Oct 31, 2026, 10:15 AM EDT
Recruiting No phase listed Observational

Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies

NCT07211178
View directory record Official record
Conditions
Breast Cancer, TNBC - Triple-Negative Breast Cancer, HR Positive/HER-2 Negative Breast Cancer, HER2 + Breast Cancer, Early Stage Breast Cancer
Interventions
There are no interventions in this observational study.
Other
Lead sponsor
Tempus AI
Industry
Eligibility
18 Years to 99 Years
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
16
States / cities
Birmingham, Alabama • Whittier, California • Weston, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 31, 2026, 10:15 AM EDT
Withdrawn Phase 1Phase 2 Interventional

NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis

NCT04129515
View directory record Official record
Conditions
Metastatic Melanoma, Melanoma Brain Metastasis
Interventions
NovoTTF-200A, Pembrolizumab
Device · Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jan 2, 2026 · Synced Oct 31, 2026, 10:15 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

AVAVA MIRIA General Use

NCT06868615
View directory record Official record
Conditions
Acne, Acne Scars - Mixed Atrophic and Hypertrophic, Scars, Wrinkle, Pigment; Lesion, Skin Texture Disorder
Interventions
AVAVA
Device
Lead sponsor
AVAVA, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 31, 2026, 10:15 AM EDT
Completed Phase 2 Interventional Results available

Protocol for Women at Increased Risk of Developing Breast Cancer

NCT00291135
View directory record Official record
Conditions
Breast Cancer
Interventions
letrozole
Drug
Lead sponsor
Carol Fabian, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 15, 2016 · Synced Oct 31, 2026, 10:15 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis

NCT01925768
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Apremilast 30 mg, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
24
States / cities
Birmingham, Alabama • Palm Desert, California • Brandon, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Oct 31, 2026, 10:15 AM EDT
Completed Not applicable Interventional Results available

Wheeled Mobility for Preventing Pressure Ulcers

NCT01275313
View directory record Official record
Conditions
Mobility Limitation
Interventions
Lightweight wheelchair, Skin Protection Cushion
Device
Lead sponsor
University of Pittsburgh
Other
Eligibility
60 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 28, 2022 · Synced Oct 31, 2026, 10:15 AM EDT
Completed Phase 2Phase 3 Interventional

Dehydroepiandrosterone (DHEA) in Systemic Lupus Erythematosus (SLE) for Coronary Artery Disease (CAD) Prevention

NCT00189124
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Dehydroepiandrosterone (DHEA)
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 18, 2016 · Synced Oct 31, 2026, 10:15 AM EDT
Terminated No phase listed Observational

Surviving Daily Life

NCT07054723
View directory record Official record
Conditions
Stress, Cognitive Change, Breast Cancer, Breast Carcinoma, Breast Neoplasm, Cognitive Dysfunction
Interventions
Mobile Daily Diary
Behavioral
Lead sponsor
Thomas Jefferson University
Other
Eligibility
40 Years and older · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Oct 31, 2026, 10:15 AM EDT
Completed Not applicable Interventional Results available

Reversal of Epidermal Phenotype in Severe Atopic Dermatitis With Cyclosporine Therapy

NCT01149759
View directory record Official record
Conditions
Atopic Dermatitis, Eczema
Interventions
Cyclosporine A
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Oct 31, 2026, 10:15 AM EDT
Active, not recruiting Not applicable Interventional

Impact of Different Exercise Programs on Knee OA

NCT05844124
View directory record Official record
Conditions
Osteoarthritis, Knee Osteoarthritis, Arthritis, Joint Diseases, Musculoskeletal Diseases, Rheumatic Diseases
Interventions
Exercise for Knee Osteoarthritis Recommendations (Control group), Exercise for Knee Osteoarthritis -(LBPP supported low-load treadmill Walking), Exercise for Knee Osteoarthritis - (Aquatic Walking)
Other
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
50 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Oct 31, 2026, 10:15 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Nonlinear Elasticity Mapping of Breast Masses

NCT04863443
View directory record Official record
Conditions
Breast Cancer
Interventions
Ultrasound
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2025
U.S. locations
2
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Oct 31, 2026, 10:15 AM EDT
Completed Phase 2 Interventional Results available

Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer

NCT00416715
View directory record Official record
Conditions
Arthralgia, Musculoskeletal Complications, Pain, Recurrent Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
letrozole, calcium carbonate, laboratory biomarker analysis, calcium citrate, calcium glucarate, calcium gluconate, cholecalciferol, assessment of therapy complications, musculoskeletal complications management/prevention
Drug · Dietary Supplement · Other + 1 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 31, 2026, 10:15 AM EDT
Completed Phase 1 Interventional

ARRY-380 + Trastuzuamab for Breast w/ Brain Mets

NCT01921335
View directory record Official record
Conditions
Brain Metastases From HER2 and Breast Cancer, Advanced HER2-positive Breast Cancer
Interventions
ARRY-380 Twice Daily Dosage, ARRY-380 Once Daily, Trastuzumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 6, 2024 · Synced Oct 31, 2026, 10:15 AM EDT
Completed Phase 2 Interventional

A Magnetic Resonance Imaging Study and Arthroscopic Biopsy Substudy in Subjects With Active Rheumatoid Arthritis Receiving VX-509, an Oral JAK3 Inhibitor

NCT01754935
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
VX-509, VX-509 matching placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
21
States / cities
Stanford, California • Upland, California • Fort Lauderdale, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated May 19, 2015 · Synced Oct 31, 2026, 10:15 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

An Exercise RCT Targeting African-American Women With Metabolic Syndrome and High Risk for Breast Cancer

NCT02103140
View directory record Official record
Conditions
Metabolic Syndrome, Obesity
Interventions
Facility-based Exercise, Home-based Exercise
Behavioral
Lead sponsor
Georgetown University
Other
Eligibility
45 Years to 65 Years · Female only
Enrollment
213 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2025
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Oct 31, 2026, 10:15 AM EDT
Recruiting Phase 2 Interventional

MTX-001 for the Treatment of Non-Healing Venous Stasis Ulcers

NCT04647240
View directory record Official record
Conditions
Venous Stasis Ulcer, Venous Leg Ulcer
Interventions
MTX-001 (human amniotic fluid)
Biological
Lead sponsor
Merakris Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
12
States / cities
Tucson, Arizona • Castro Valley, California • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 31, 2026, 10:15 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Tabalumab (LY2127399) Using Two Different Injection Methods in Participants With Lupus

NCT02041091
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Tabalumab Auto-Injector, Tabalumab Prefilled Syringe
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
36
States / cities
Covina, California • El Cajon, California • Long Beach, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2018 · Synced Oct 31, 2026, 10:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Comparing Modes of Telehealth Delivery: Phone vs. Video Visits (ASSIST)

NCT04616118
View directory record Official record
Conditions
Rheumatic Disease, Cardiac Disease, Primary Care, Infectious Disease
Interventions
Phone Visit, Video Visit
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
269 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 13, 2021 · Synced Oct 31, 2026, 10:15 AM EDT
Terminated Phase 2 Interventional

Multiple-Dose Pharmacokinetics and Potential for Adrenal Suppression Following Treatment With Halobetasol Spray in Patients With Atopic Dermatitis

NCT03245385
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Treatment with Halobetasol propionate 0.05% topical spray
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
12 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
13
States / cities
North Hollywood, California • Pasadena, California • Hialeah, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Oct 31, 2026, 10:15 AM EDT
Recruiting Not applicable Interventional

Community-led Navigation to Address Disparities in Mammography Among Native American Women

NCT06957535
View directory record Official record
Conditions
Breast Cancer
Interventions
Navigation, TEAM
Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
40 Years to 74 Years · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Chinle, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 31, 2026, 10:15 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer

NCT02752685
View directory record Official record
Conditions
Breast Cancer
Interventions
Pembrolizumab, Nab-Paclitaxel
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Oct 31, 2026, 10:15 AM EDT